AACR 2022 | Future directions in triple-negative breast cancer research

Sangeetha M. Reddy, MD, UT Southwestern Medical Center, Dallas, TX, discusses how immunotherapy research has moved away from the metastatic setting to localized triple-negative breast cancer (TNBC). For patients with TNBC, we now have an immune checkpoint blockade approved with four different chemotherapies. Current research is also investigating if we can de-escalate treatments to a less than five drug regime. Furthermore, there has been a strong success in TNBC research with antibody-drug conjugates such as sacituzumab. These antibody-drug conjugates are changing how we treat patients with TNBC as ongoing investigations are assessing how we can combine these agents with other immunotherapies. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.